Medidata
Medidata Solutions, Inc., headquartered in the United States, is a leading player in the life sciences industry, specialising in cloud-based solutions for clinical trials. Founded in 1999, the company has achieved significant milestones, including the development of innovative technologies that streamline the drug development process. With a strong presence in North America, Europe, and Asia, Medidata offers a comprehensive suite of products and services, including data management, analytics, and patient engagement tools. Their unique platform integrates advanced analytics and artificial intelligence, enabling biopharmaceutical companies to enhance decision-making and improve trial outcomes. Recognised for its market leadership, Medidata has been instrumental in transforming clinical research, supporting over 25,000 trials and 5 million patients globally. The company’s commitment to innovation and excellence positions it as a trusted partner in the evolving landscape of clinical development.
DitchCarbon Score
How does Medidata's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medidata's score of 37 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medidata's reported carbon emissions
As of 2019, Medidata reported total carbon emissions of approximately 15,014,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 242,160 kg CO2e, while Scope 2 emissions totalled approximately 1,834,440 kg CO2e. The majority of their emissions stemmed from Scope 3, which accounted for around 13,937,800 kg CO2e, primarily from business travel, employee commuting, and purchased goods and services. In 2018, Medidata's emissions were approximately 12,997,760 kg CO2e in Scope 3, with Scope 1 emissions at about 462,420 kg CO2e and Scope 2 emissions around 1,808,250 kg CO2e. The trend indicates a significant reliance on Scope 3 emissions, highlighting the importance of addressing indirect emissions in their climate strategy. Despite the detailed emissions reporting, there are currently no specific reduction targets or initiatives disclosed by Medidata. The absence of documented reduction commitments suggests a need for further clarity on their climate action plans. Overall, Medidata's emissions data reflects a substantial carbon footprint, particularly in Scope 3, underscoring the importance of comprehensive strategies to mitigate climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | |
|---|---|---|---|
| Scope 1 | - | 000,000 | 000,000 |
| Scope 2 | 1,831,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 6,330,040 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medidata is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
